Recent advances in the design of HIV proteinase inhibitors.

Inhibition of HIV proteinase is currently one of the most widely studied approaches for chemotherapeutic intervention in the treatment of AIDS. A range of inhibitors of this essential enzyme has been designed from detailed knowledge of its mechanism of action and cleavage sites. These inhibitors have been classified according to their derivation. All are transition-state analogues and contain a hydroxyethylene, hydroxyethylamine, phosphinate or symmetrical moiety. Many of these inhibitors have high selectivity for the viral enzyme and significant antiviral activity. Advances in the design of HIV proteinase inhibitors that have been reported in the past year are reviewed.

[1]  Mark L. Pearson,et al.  Complete nucleotide sequence of the AIDS virus, HTLV-III , 1985, Nature.

[2]  E. Wimmer,et al.  Activity of purified biosynthetic proteinase of human immunodeficiency virus on natural substrates and synthetic peptides. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[3]  C. Debouck,et al.  Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitors. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[4]  J Leibowitch,et al.  Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). , 1983, Science.

[5]  Tomi K. Sawyer,et al.  A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. , 1990, Disease markers.

[6]  D. Norbeck,et al.  Synthesis of (2S,5S,4R)-2,5-diamino-3,3-difluoro-1,6-diphenylhydroxyhexane: the core unit of a potent HIV proteinase inhibitor , 1991 .

[7]  William R. Taylor,et al.  A structural model for the retroviral proteases , 1987, Nature.

[8]  D. Decamp,et al.  Specificity and inhibition of proteases from human immunodeficiency viruses 1 and 2. , 1990, The Journal of biological chemistry.

[9]  E. Reddy,et al.  HTLV-III gag protein is processed in yeast cells by the virus pol-protease. , 1986, Science.

[10]  D. Grobelny,et al.  Selective phosphinate transition-state analogue inhibitors of the protease of human immunodeficiency virus. , 1990, Biochemical and biophysical research communications.

[11]  I B Duncan,et al.  Rational design of peptide-based HIV proteinase inhibitors. , 1990, Science.

[12]  P. Štrop,et al.  Synthetic peptides as substrates and inhibitors of human immune deficiency virus-1 protease. , 1988, The Journal of biological chemistry.

[13]  M. Jaskólski,et al.  Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. , 1989, Science.

[14]  J. Chermann,et al.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). , 1983, Science.

[15]  D. Veber,et al.  HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins. , 1988, Biochemical and biophysical research communications.

[16]  G R Marshall,et al.  Hydroxyethylamine analogues of the p17/p24 substrate cleavage site are tight-binding inhibitors of HIV protease. , 1990, Journal of medicinal chemistry.

[17]  E A Emini,et al.  Benzocycloalkyl amines as novel C-termini for HIV protease inhibitors. , 1991, Journal of medicinal chemistry.

[18]  B. Dunn,et al.  Effective blocking of HIV‐1 proteinase activity by characteristic inhibitors of aspartic proteinases , 1989, FEBS letters.

[19]  S. Kent,et al.  Enzymatic activity of a synthetic 99 residue protein corresponding to the putative HIV-1 protease , 1988, Cell.

[20]  G. Marshall,et al.  Effect of hydroxyl group configuration in hydroxyethylamine dipeptide isosteres on HIV protease inhibition. Evidence for multiple binding modes. , 1991, Journal of medicinal chemistry.

[21]  W. M. Sanders,et al.  L-687,908, a potent hydroxyethylene-containing HIV protease inhibitor. , 1991, Journal of medicinal chemistry.

[22]  S. Vasavanonda,et al.  Structure-based, C2 symmetric inhibitors of HIV protease. , 1990, Journal of medicinal chemistry.

[23]  C. Debouck,et al.  Peptide substrates and inhibitors of the HIV-1 protease. , 1989, Biochemical and biophysical research communications.